Description
EPO (Erythropoietin) is a 165-amino-acid glycoprotein synthesized primarily in the kidneys and functioning as the central regulator of erythropoiesis (erythrocyte formation in bone marrow). In research literature, EPO is one of the best-characterized growth factors at all, with extensive data on mechanism, pharmacokinetics and animal model effects.
The research mechanism lies in the activation of the EPO receptor on erythroid progenitor cells in the bone marrow. Binding leads to receptor dimerization, JAK2 activation and downstream STAT5 signaling, promoting the differentiation and survival of erythroid cells. Secondarily, EPO also activates other pathways in non-hematopoietic tissues, including the innate repair receptor (IRR), which mediates tissue-protective effects.
In preclinical studies, EPO has been comprehensively characterized in models of renal anemia, chemotherapy-induced anemia and chronic disease-associated anemia. Indeed, recombinant human EPO was one of the first successful biologic compounds and has a substantial research history.
In performance research context, EPO is interesting as a compound addressing erythrocyte mass and oxygen transport capacity. The data on effects on hematocrit, hemoglobin and endurance endpoints is extensive. EPO is among the prominent compounds in sports science, with clearly defined mechanisms and well-documented endpoints.
EPO is available in 4000iu vials as 10-vial packs.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
EPO is pharmacologically very well characterized as a growth factor, but it is among the more seriously rated compounds in this selection, because the increase in erythrocyte mass brings a direct and well-documented vascular risk.
Documented in the clinical literature and sports science:
- Hematocrit increase: EPO raises hematocrit through stimulation of erythropoiesis. The literature documents that an excessively high hematocrit substantially increases blood viscosity.
- Thromboembolism and stroke risk: the elevated hematocrit is clearly associated in clinical studies with an increased risk of thromboembolic events, including stroke. This is the central safety point with EPO.
- Blood pressure: clinical studies document blood pressure increases under EPO application.
- Injection site: redness or pressure at the injection site is among the more common observations.
- Difficult-to-control profile: the effect on hematocrit sets in with a delay and persists, which the literature describes as demanding to control.
This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Erythropoietin: structure, function, biology - Trends in Endocrinology and Metabolism 2007: Mechanism overview.
- Recombinant human erythropoietin: 30 years of research - Blood 2019: Research history.
- EPO and tissue protection beyond erythropoiesis - Nature Reviews Neuroscience 2005: Non-hematopoietic pathways.
